Product Data Sheet

RIP2 Kinase Inhibitor 4

Cat. No.: HY-136010 CAS No.: 2126803-41-4 Molecular Formula: $\mathsf{C}_{50}\mathsf{H}_{66}\mathsf{F}_{2}\mathsf{N}_{14}\mathsf{O}_{7}\mathsf{S}$

Molecular Weight: 1045.21

Target: RIP kinase; PROTACs Pathway: Apoptosis; PROTAC

Storage: Please store the product under the recommended conditions in the Certificate of

BIOLOGICAL ACTIVITY

Description	RIP2 Kinase Inhibitor 4 is a potent and selective RIPK2 PROTAC. RIP2 Kinase Inhibitor 4 effectively degrades RIPK2 (pIC ₅₀ of 8) and inhibits the release of related TNF- α ^[1] .
IC ₅₀ & Target	CIAP1 RIPK2 8 (pIC ₅₀)
In Vitro	RIP2 Kinase Inhibitor 4 (Compound 20) utilizes a novel inhibitor of apoptosis (IAP) binder. RIP2 Kinase Inhibitor 4 possess comparatively reduced binding potency at both cIAP1 and XIAP BIR3 domains and increased potency at the XIAP BIR2 domain ^[1] . RIP2 Kinase Inhibitor 4 (Compound 20) recruits the IAP E3 ligases and shows markedly reduced inhibition of muramyl dipeptide (MDP)-stimulated TNF α production in human peripheral blood mononuclear cells (PBMCs) (pIC $_{50}$ of 9.3) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	The initial in vivo assessment of RIP2 Kinase Inhibitor 4 (Compound 20) in rats dosed at 0.5 mg/kg SC demonstrated high levels of RIPK2 degradation and inhibition of MDP-stimulated TNF α release at the final 48 h time point ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Afjal H Miah, et al. Optimization of a Series of RIPK2 PROTACs. J Med Chem. 2021 Sep 9;64(17):12978-13003.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA